Pliant Therapeutics, Inc. ( PLRX) Stock. Should you Buy or Sell? $ 22.23
1.86 (7.72 %)
Pliant Therapeutics, Inc. Analysis
Updated on 10-09-2022| Symbol | PLRX |
| Price | $22.23 |
| Beta | 1.626 |
| Volume Avg. | $2.09 M |
| Market Cap | $1.08 B |
| 52 Week Range | $3.965 - $23.0 |
Pliant Therapeutics, Inc. opened the day at $22.23 which is +'7.72 % on yesterday's close. Pliant Therapeutics, Inc. has a 52 week high of $23.0 and 52 week low of $3.965, which is a difference of $19.035. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $1.08 B and total net profit is $7572000 which means the company is trading at 142.92 times profit to market capitalization. Theoretically, if you were to buy Pliant Therapeutics, Inc. for $1.08 B, it would take 15 years to get your money back. Pliant Therapeutics, Inc. are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.
Price Chart
Financials
Pliant Therapeutics, Inc. Stock Forecast - Is Pliant Therapeutics, Inc. a Buy or Sell?
| DCF Score | Strong Buy | |
| ROE Score | Sell | |
| ROA Score | Sell | |
| DE Score | Neutral | |
| PE Score | Sell | |
| PB Score | Strong Buy | |
| Overall Recommendation | Neutral |
Growth and Value
| PE Ratio | -7.362 |
| Dividend Yiel | 0.000 |
| Net Profit Margin | -11.092 |
Valuing Pliant Therapeutics, Inc.
| Price Book Value Ratio | 5.441 | Price To Book Ratio | 5.441 |
| Price To Sales Ratio | 81.662 | Price Earnings Ratio | -7.362 |
How liquid is Pliant Therapeutics, Inc.
| Current Ratio | 7.694 |
| Quick Ratio | 7.493 |
Debt
| Debt Ratio | 0.199 | Debt Equity Ratio | 0.249 |
| Long Term Debt To Capitalization | 0.088 | Total Debt To Capitalization | 0.099 |
Latest news about Pliant Therapeutics, Inc.
Here is how Pliant Therapeutics, Inc. (PLRX) and Alaunos (TCRT) have performed compared to their sector so far this year.
Pliant Therapeutics, Inc. (PLRX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Pliant (PLRX) receives a positive DSMB review of the ongoing mid-stage study evaluating the company's lead candidate PLN-74809 for treating idiopathic pulmonary fibrosis.
The average of price targets set by Wall Street analysts indicates a potential upside of 127.3% in Pliant Therapeutics, Inc. (PLRX). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2022 (GLOBE NEWSWIRE) -- Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced that Bernard Coulie, M.D., Ph.D., President and Chief Executive Officer, and members of Pliant's senior management will participate in the following September investor conferences:
About Pliant Therapeutics, Inc.
Description :
Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. Its lead product candidate is PLN-74809, an oral small-molecule dual selective inhibitor of avß6 and avß1 integrins, which is in three Phase 2a trials. The company also develops PLN-1474, a small-molecule selective inhibitor of avß1, which completed Phase 1 clinical trial for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis. In addition, it is developing two additional preclinical integrin-based programs, which include an oncology program, as well as a program for an allosteric agonistic monoclonal antibody against an undisclosed integrin receptor for treatment of muscular dystrophies, including duchenne muscular dystrophy. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.
